CompletedPhase 2NCT04085523

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

Studying Achondroplasia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ascendis Pharma A/S
Principal Investigator
Aimee D. Shu, MD
Ascendis Pharma, Inc.
Intervention
TransCon CNP(drug)
Enrollment
57 enrolled
Eligibility
2-10 years · All sexes
Timeline
2020 – 2024

Study locations (15)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04085523 on ClinicalTrials.gov

Other trials for Achondroplasia

Additional recruiting or active studies for the same condition.

See all trials for Achondroplasia →

← Back to all trials